Open
Do SGLT2 inhibitors improve pharmacokinetics & dosing versus placebo?
Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 1
- Inconclusive
- 1
Already under way
No registered trial that could settle this is recruiting or active.
The evidence so far
- Registered trials
- 97
- With posted results
- 22
- Published papers
- 1
Of 7 decided analyses: 0 favor sglt2 inhibitors, 7 find no difference, 0 favor the comparator.
Papers
- SGLT2 inhibitors vs. metformin for Parkinson's disease risk reduction in type 2 diabetes.Observational study · 2025
Trials
- A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy SubjectsNCT01662999 · 17 posted results
- A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a SulfonylureaNCT02532855 · 3 posted results
- DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients.NCT03338855 · 1 posted result
- Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of AgeNCT06012266
- Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin SecretionNCT02113241 · 4 posted results
- Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes MellitusNCT02863328 · 2 posted results
- A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed StatesNCT01535677
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.NCT02033889 · 1 posted result